Insights and events
Clients especially like Miriam Gundt's pragmatic and solution-oriented approach. Miriam is well connected in our global network. She is an ideal "go-to" lawyer for the coordination of international patent disputes and the enforcement of intellectual property rights in various European jurisdictions. Her strategic advice comprises questions regarding the new Unified Patent Court (UPC) and the European Patent with Unitary Effect. She represents and advises clients on all matters of intellectual property and technical industrial property rights, with a focus on patents and utility models. Her experience comprises both patent litigation and contractual IP matters, including license agreements and R&D Agreements.
Further, she possesses outstanding knowledge in the area of Supplementary Protection Certificates (SPCs). Miriam focuses on the pharma and biotech industry, life science and medical engineering. She is highly skilled in the area of interim legal protection, including preliminary injunctions and evidence seizures. Miriam has successfully obtained and enforced preliminary injunctions for various clients. She also supports clients on any IP-related issues caused by the implementation of the U.S. Inflation Reduction Act.
Miriam is a member of various associations in the field of intellectual property (GRUR, EPLAW, AIPLA, VPP) and regularly speaks on patent law related topics at national and international conferences and seminars. Miriam is very committed to diversity, equity, and inclusion and has been appointed as Head of Diversity & Inclusion in Europe at the beginning of 2018.
Managing international patent litigation for major pharmaceutical company on its blockbuster product, including infringement proceedings in Germany, Japan, and EPO opposition proceedings.
Advising a major pharmaceutical/biotech company on a multi-jurisdictional defense strategy regarding patent litigation in the field of stem cells for use in treatment of chronic inflammatory diseases.
Representing a leading medical device company in patent infringement proceedings including recovering damages.
Winning the first compulsory licence case that was ever granted in interim proceedings at the German Federal Patent Court on Merck's HIV/AIDS medicament Isentress®.
Advising a leading medical device company FTO analyses in connection with the launch of a new product line.
- University of Aberdeen
- University of Milan
- Osnabrück University
- Women in IP